Keywords: Cabozantinib; Medullary; Metastatic; Multikinase; REMS; Vandetanib;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Cabozantinib; Disease-free survival; Network meta-analysis; Nivolumab; Renal cell carcinoma;
Keywords: Renal cell carcinoma; Cabozantinib; Nivolumab; Ipilimumab; Bevacizumab; Atezolizumab;
Keywords: Cabozantinib; Vascular endothelial growth factor receptor; Solid tumour; Objective response rate; Progression-free survival; Randomised discontinuation trial;
Keywords: cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: medullary thyroid cancer; RET; tyrosine kinase inhibitors; vandetanib; cabozantinib; chemotherapy;
Keywords: Medullary thyroid cancer; RET mutations; Vandetanib; Cabozantinib; Tyrosine kinase inhibitors
Keywords: Renal cell carcinoma; Sdjuvant therapy; Cytoreductive nephrectomy; Vaccines; Immunotherapy; PD-1; Cabozantinib
Keywords: Pancreatic cancer stem cell; CD44; c-Met; cabozantinib; Stemness; Metastases
Keywords: Renal cell carcinoma; Tyrosine kinase inhibitor; Axitinib; Tivozanib; Dovitinib; Cabozantinib;
Keywords: Angiogenesis; Castration resistant prostate cancer; Vascular endothelial growth factor; Bevacizumab; Sunitinib; Cabozantinib;
Occurrence and significance of morphologic changes in patients with metastatic triple negative breast cancer treated with Cabozantinib
Keywords: Cabozantinib; Breast cancer; Tumor response criteria; RECIST; Choi;
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
Keywords: MET inhibition; Cabozantinib; Clear cell ovarian cancer; Anti-angiogenic therapy;
Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib
Keywords: Renal cell carcinoma; AXL; Sunitinib; Cabozantinib; Prognostic biomarker;
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
Keywords: Cabozantinib; First-line; Sunitinib; IMDC risk groups; Advanced renal cell carcinoma;
Clinical TrialA phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma
Keywords: Cabozantinib; Ovarian cancer; Vascular endothelial growth factor receptor; MET; Tyrosine kinase inhibitor; Randomised discontinuation trial;
Cabozantinib : modalités d'action, efficacité et indications
Keywords: Cabozantinib; Récepteur MET; Cancer médullaire de la thyroïde; Cancer du rein; Cancer de la prostate; Cancer bronchique non à petites cellules; Cabozantinib; MET receptor; Medullary thyroid cancer; Advanced cell renal carcinoma; Prostate cancer; Lung
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
Keywords: MDR; multidrug resistant; ABC transporter; ATP binding cassette transporter; ABCG2; ATP binding cassette subfamily G member 2; Cabozantinib; Breast cancer resistant protein; Multidrug resistance; ABC transporter;
Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases
Keywords: MET exon 14; NSCLC; Crizotinib; Cabozantinib; Brain metastases; Comprehensive genomic profiling;
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients
Keywords: Cabozantinib; Lung cance; PDL-1; Personalized medicine; RET;
Cabozantinib is selectively cytotoxic in acute myeloid leukemia cells with FLT3-internal tandem duplication (FLT3-ITD)
Keywords: Acute myeloid leukemia; FLT3-ITD; Cabozantinib
An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: Application to a pharmacokinetic study
Keywords: Cabozantinib; LC-MS/MS; Rat plasma; Pharmacokinetics
Pharmacokinetics and tissue distribution model of cabozantinib in rat determined by UPLC–MS/MS
Keywords: Cabozantinib; UPLC–MS/MS; Pharmacokinetics; BP-ANN
Les nouvelles thérapies dans le cancer de la prostate métastatique
Keywords: CRPC; Abiratérone; Enzalutamide; Cabozantinib; MOSCATO; CRPC; Abiraterone; Enzalutamide; Cabozantinib; MOSCATO;
Consensus on the management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI)
Keywords: Cabozantinib; Calcitonin; Carcinoembryonic antigen; Expert consensus; Guidelines; Medullary thyroid carcinoma; Thyroid cancer; VandetanibCabozantinib; Calcitonina; Antígeno carcinoembrionario; Consenso de expertos; Guía; Carcinoma medular de tiroides; Cán
Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo
Keywords: CBZ; Cabozantinib; GFP Ob+; green fluorescent protein expressing cells of the osteoblastic lineage; CTRL; control; PBS; phosphate buffered saline; TRAP; tartrate resistant alkaline phosphatase; PINP; procollagen type 1 N-terminal propeptide; MET; hepatocy
Thyroid Gland Malignancies
Keywords: Anaplastic; Medullary; Differentiated; Thyroid cancer; Cabozantinib; Lenvatinib; Sorafenib; Vandetanib;
Degradation kinetics study of cabozantinib by a novel stability-indicating LC method and identification of its major degradation products by LC/TOF-MS and LC–MS/MS
Keywords: Cabozantinib; Stability-indicating LC; Degradation; LC/TOF-MS; LC–MS/MS
A “Game of Thrones” in Metastatic Renal Cell Carcinoma: Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors and Mammalian Target of Rapamycin Inhibitors Battling for Position
Keywords: BMS-936558; Cabozantinib; COMPARZ; INTORACT; INTORSECT; PISCES;
Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer
Keywords: Prostate cancer; Cabazitaxel; Cabozantinib; Dasatinib; Clusterin; Hsp27; OGX-011;